Skip to main content
Premium Trial:

Request an Annual Quote

Reviewer: Ditch the 11-point Font, Embrace the Flowchart

Blogger DrdrA at Blue Lab Coats writes about being on the "other side of the grant," as a reviewer, and drafts a list of "Reviewer Blues." On the list? Eleven-point Arial font, 25 sub-aims listed beneath three overall aims ("sometimes less is more," she writes), and pages packed with text and no breathing room. The reviewer does, however, appreciate applications complete with flow charts outlining the experimental design and those that provide only one figure per page. "An organized SRO is a god-send," DrdrA adds.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.